Acute Management of Right Ventricular Dysfunction in Pulmonary Hypertension Associated with Interstitial Lung Disease

Abstract

by poor survival and reduced quality of life, while scientific evidence supporting specific therapies for this subgroup remains limited.Moreover, right ventricular (RV) dysfunction is often found to be more severe in Group 3 PH, despite pulmonary vascular resistancebeing generally lower than in Group 1 PH. Various precipitating factors, such as acute hypoxemia, infection, arrhythmia, andexacerbation of underlying lung disease, may worsen pulmonary arterial pressure and trigger acute right ventricular failure. Currenttherapeutic strategies focus on managing these precipitating factors, controlling arrhythmias, optimizing ventilation andhemodynamics through appropriate preload optimization, inotropic and vasopressor support, and the selective use of pulmonaryvasodilators.